<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>The aim of the study was to determine kidney survival and validate the novel international immunoglobulin A nephropathy (IgAN) prediction tool (PT) in the Latvian population. Adults with morphologically confirmed IgAN were included. Kidney survival was analysed with the Kaplan–Meier method. PT-assigned risk was compared with calculated risk by the Cox regression model. The Kaplan–Meier analysis included 95 patients. The five-year kidney survival Q3 was 24 months. Women had longer median kidney-survival time (> 60 months) than men (58 months). Median kidney survival in participants with MEST T0 was longer than 60 months; T1 and T2 were 40 and 18 months, respectively. Median kidney survival in participants with diastolic blood pressure (DBP) &lt; 99 mmHg was longer than 60 months, whereas in patients with DBP 100–109 and 110 mmHg, it was 40 and 24 months, respectively. Cox regression analysis included 68 patients. A moderate degree of correlation was found between predicted and observed five-year risk (p = 0.001). Gender, tubular atrophy/interstitial fibrosis, DBP are significant factors affecting kidney survival. Since there was statistically significant correlation and reliability between PT and follow-up analysis data, we conclude that PT could be applied for use in the Latvian population.</p>
</abstract>

The aim of the study was to determine kidney survival and validate the novel international immunoglobulin A nephropathy (IgAN) prediction tool (PT) in the Latvian population. Adults with morphologically confirmed IgAN were included. Kidney survival was analysed with the Kaplan–Meier method. PT-assigned risk was compared with calculated risk by the Cox regression model. The Kaplan–Meier analysis included 95 patients. The five-year kidney survival Q3 was 24 months. Women had longer median kidney-survival time (> 60 months) than men (58 months). Median kidney survival in participants with MEST T0 was longer than 60 months; T1 and T2 were 40 and 18 months, respectively. Median kidney survival in participants with diastolic blood pressure (DBP) < 99 mmHg was longer than 60 months, whereas in patients with DBP 100–109 and 110 mmHg, it was 40 and 24 months, respectively. Cox regression analysis included 68 patients. A moderate degree of correlation was found between predicted and observed five-year risk (p = 0.001). Gender, tubular atrophy/interstitial fibrosis, DBP are significant factors affecting kidney survival. Since there was statistically significant correlation and reliability between PT and follow-up analysis data, we conclude that PT could be applied for use in the Latvian population.

Renal Survival and Validation of Novel International Immunoglobulin a Nephropathy Prediction Tool in Latvian Population: Preliminary Data

Pauls Stradiņš Clinical University Hospital

Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

The aim of the study was to determine kidney survival and validate the novel international immunoglobulin A nephropathy (IgAN) prediction tool (PT) in the...

Renal Survival and Validation of Novel International Immunoglobulin a Nephropathy Prediction Tool in Latvian Population: Preliminary Data

Pubblicato online: 15 nov 2021

Pagine: 379 - 386

Ricevuto: 29 dic 2020

Accettato: 27 mar 2021

DOI: https://doi.org/10.2478/prolas-2021-0055

Parole chiave
immunoglobulin A nephropathy, novel IgAN prediction tool, kidney survival risk factors, end-stage kidney disease

© 2021 Anna Jana Saulīte et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Renal Survival and Validation of Novel International Immunoglobulin a Nephropathy Prediction Tool in Latvian Population: Preliminary Data

Pubblicato online: 15 nov 2021

Pagine: 379 - 386

Ricevuto: 29 dic 2020

Accettato: 27 mar 2021

DOI: https://doi.org/10.2478/prolas-2021-0055

Parole chiaveimmunoglobulin A nephropathy, novel IgAN prediction tool, kidney survival risk factors, end-stage kidney disease

© 2021 Anna Jana Saulīte et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Parole chiave
immunoglobulin A nephropathy, novel IgAN prediction tool, kidney survival risk factors, end-stage kidney disease